Clinical trials: sponsored by Amgen
Carcinoma, Fallopian Tube Cancer
Study of AMG 386 in Combination With Paclitaxel and Carboplatin in Subjects With Ovarian Cancer
To evaluate whether AMG 386 in combination with paclitaxel and carboplatin is safe and well tolerated in the first-line treatment of high-risk stage I and stages II-IV epithelial ovarian, primary peritoneal and fallopian tube…
- Conditions
- Carcinoma, Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cancer
- Trial name
- NCT01253681
- Testing
- AMG 386, paclitaxel and carboplatin
- Where
- 8 sites in Australia, Belgium and 1 more
- Volunteers
- 27 people
- Sponsor
- Amgen
Cancer, Carcinoma
AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR
This study is a 2 part, 2 cohort, open-label, dose escalation/de escalation study of AMG 386 in combination with either pegylated liposomal doxorubicin or topotecan in subjects with recurrent ovarian cancer.
- Conditions
- Cancer, Carcinoma, Fallopian Tube Cancer, Gynecological Malignancies
- Trial name
- NCT00770536
- Testing
- A1: AMG 386 10 mg/kg + Liposomal doxorubicin, A3: AMG 386 15mg/kg + Liposomal doxorubicin, B1: AMG 386 10 mg/kg + Topotecan
- Where
- 16 sites in United States, Australia and 1 more
- Volunteers
- 103 people
- Sponsor
- Amgen
Healthy Volunteer, Female, Breast
Effect of Denosumab on Cellular Biomarkers in the Human Breast
To evaluate whether administration of denosumab results in a decrease compared to the control group in proliferation of mammary epithelial cells as measured by the Ki-67 proliferation index.
- Trial name
- NCT02099461
- Testing
- Denosumab, Percutaneous core needle breast biopsy
- Where
- 3 sites in United States
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Amgen
Non-Small Cell Lung Cancer
MONET1-MOtesanib NSCLC Efficacy and Tolerability Study
To determine if treatment with AMG 706 (motesanib diphosphate) in combination with paclitaxel and carboplatin improves overall survival compared to treatment with placebo in combination with paclitaxel and carboplatin in subjects…
- Trial name
- NCT00460317
- Testing
- AMG 706, paclitaxel, carboplatin
- Volunteers
- 1,450 people
- Sponsor
- Amgen
Cancer, Carcinoma
A Phase 2, Randomized, Double Blind, Placebo Controlled Study of AMG 386 in Combination With FOLFIRI in Subjects With Previously Treated Metastatic Colorectal Carcinoma
This clinical trial will compare the efficacy and safety of the combination of AMG 386 and FOLFIRI with FOLFIRI alone in second line treatment of metastatic colorectal cancer.
- Conditions
- Cancer, Carcinoma, Colon Cancer, Colorectal Cancer
- Trial name
- NCT00752570
- Testing
- AMG 386, FOLFIRI
- Volunteers
- 144 people
- Sponsor
- Amgen
Schizophrenia
20101299: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms
The purpose of this study is to evaluate the effect of AMG 747 on negative symptoms of schizophrenia in patients who are stable on current antipsychotic treatment.
- Trial name
- NCT01568216
- Testing
- AMG 747
- Where
- 38 sites in United States, Australia and 5 more
- Volunteers
- 121 people
- Sponsor
- Amgen
Axial Spondyloarthritis
Study of Efficacy and Safety of Brodalumab Compared With Placebo in Subjects With Axial Spondyloarthritis
The purpose of this study is to assess the safety and efficacy of brodalumab compared with placebo in participants with axial spondyloarthritis.
- Trial name
- NCT02429882
- Testing
- Brodalumab 210 mg
- Where
- 5 sites in United States, Canada
- Sponsor
- Amgen
XGEVA Off-label Use
Estimation of Off-Label Use of XGEVA® (Denosumab) Using Population-Based Databases in Denmark
This study aims to evaluate off-label XGEVA use in Denmark using data linked from registries and other sources in Northern Jutland Region and Copenhagen.
- Trial name
- NCT02066805
- Testing
- Database assessment of off-label XGEVA use
- Volunteers
- 142 people
- Sponsor
- Amgen
Locally Advanced or Metastatic, Unresectable Soft Tissue Sarcoma, Sarcoma
Phase 1b/2 Study of AMG 655 With Doxorubicin for the First-Line Treatment of Unresectable Soft Tissue Sarcoma
This phase 1/2, multicenter, randomized, double-blind, placebo-controlled trial is designed to evaluate the efficacy and safety of AMG 655 when combined with doxorubicin compared with doxorubicin alone in subjects with previously…
- Conditions
- Locally Advanced or Metastatic, Unresectable Soft Tissue Sarcoma, Sarcoma, Soft Tissue Sarcoma
- Trial name
- NCT00626704
- Testing
- AMG 655, Doxorubicin
- Volunteers
- 134 people
- Sponsor
- Amgen
Systemic Lupus Erythematosus
A Study to Examine the Safety, Pharmacokinetics and Pharmacodynamics of Single Dose of AMG 623 in Subjects With Systemic Lupus Erythematosus
This study is to evaluate the safety of AMG 623 in subjects with systemic lupus erythematosus. The study consists of a 21 day screening period followed by administration of the investigational product and up to 70 day follow up…
- Trial name
- NCT02443506
- Testing
- AMG 623
- Volunteers
- 56 people
- Sponsor
- Amgen
Advanced Malignant Glioma
A Phase II Study to Treat Advanced Malignant Glioma
The purpose of this study is to evaluate the effectiveness and safety of AMG 102 for the treatment of Advanced Malignant Glioma.
- Trial name
- NCT00427440
- Testing
- AMG 102 at 20 mg/kg, AMG 102 at 10 mg/kg
- Volunteers
- 61 people
- Sponsor
- Amgen
Advanced Renal Cell Carcinoma
A Phase II Study to Treat Subjects With Advanced Renal Cell Carcinoma
The purpose of this study is to evaluate the effectiveness and safety of AMG 102 in patients with Advanced Renal Cancer.
- Trial name
- NCT00422019
- Testing
- AMG 102 at 10 mg/kg, AMG 102 at 20 mg/kg
- Volunteers
- 61 people
- Sponsor
- Amgen
Systemic Lupus Erythematosus
A Study to Examine the Safety, Pharmacokinetics and Pharmacodynamics of AMG 623 in Subjects With Systemic Lupus Erythematosus
This study is to evaluate the safety of AMG 623 in subjects with systemic lupus erythematosus. All subjects will receive 4 weekly doses of study drug over a 3 week period, and then will be followed for an additional 28 weeks, for…
- Trial name
- NCT02411136
- Testing
- AMG 623
- Volunteers
- 64 people
- Sponsor
- Amgen
Migraine
Phase I, Double-Blind,Placebo, MAD Study to Evaluate the Safety, Tolerability, PK, and PD of AMG 333 in Healthy Subjects and Migraine Subjects
The primary purpose of this study is to evaluate the safety and tolerability of multiple oral doses of AMG 333 for 14 days in healthy subjects and migraine subjects.
- Trial name
- NCT02132429
- Testing
- AMG 333
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Amgen
Systemic Lupus Erythematosus
A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of AMG 557 in Subjects With Systemic Lupus Erythematosus
This is a multicenter, randomized, double-blind, placebo-controlled, sequential rising single-dose study in which approximately 56 subjects with SLE will be enrolled in 7 dosing cohorts
- Trial name
- NCT02391259
- Testing
- AMG 557
- Where
- 13 sites in United States, United Kingdom
- Volunteers
- 57 people
- Sponsor
- Amgen
Ulcerative Colitis, Crohn's Disease
Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181.
To assess the safety and tolerability of multiple subcutaneous doses of AMG 181 in healthy subjects, in subjects with active ulcerative colitis, and in subjects with active Crohn's disease.
- Trial name
- NCT01290042
- Testing
- AMG 181
- Where
- 8 sites in United States, Australia
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Amgen
Castrate-resistant Prostate Cancer
Denosumab for Prolonging Bone Metastasis-Free Survival in Men With Hormone-Refractory Prostate Cancer
This is a multi-national, multi-center, open-label, single-arm extension study for the prolongation of bone metastasis-free survival in men with hormone-refractory (androgen independent) prostate cancer.
- Trial name
- NCT01824342
- Testing
- Denosumab
- Where
- 9 sites in Czechia, United Kingdom
- Volunteers
- 18 people
- Sponsor
- Amgen
Inflammatory Disease
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), Food Effect of AMG 357 in Healthy Subjects
Study to evaluate the safety, tolerability, PK, PD, and food effect of AMG 357 in healthy subjects
- Trial name
- NCT01695876
- Testing
- AMG 357
- Where
- 3 sites in New Zealand
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Amgen
Advanced Solid Tumors
A Phase 1 Dose Escalation Study of AMG 780 in Adult Subjects With Advanced Solid Tumors
This is a first in human, open-label, sequential dose escalation and expansion study of AMG 780 in up to 62 subjects with advanced solid tumors.
- Trial name
- NCT01137552
- Testing
- AMG 780
- Where
- 3 sites in United States
- Volunteers
- 44 people
- Sponsor
- Amgen
Solid Tumor, Metastatic Bone Disease
Evaluate Time Associated With the Preparation & Administration of Denosumab/Pamidronate in Patients With Solid Tumors and Metastatic Bone Disease
This study will estimate the total time for the preparation and administration of denosumab and the total time for the preparation and administration of pamidronate.
- Trial name
- NCT02101164
- Testing
- denosumab, pamidronate
- Sponsor
- Amgen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.